Allspring Global Investments
AMLX icon

Allspring Global Investments’s Amylyx Pharmaceuticals AMLX Stock Holding History

Allspring Global Investments’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-28,785
Closed -$54.7K – 2449
2024
Q2 		$54.7K Buy
28,785
+13,509
+88% +$26.2K ﹤0.01% 1953
2024
Q1 		$43.4K Buy
15,276
+15,247
+52,576% +$199K ﹤0.01% 1975
2023
Q4 		$426 Sell
29
-14,158
-100% -$217K ﹤0.01% 2162
2023
Q3 		$260K Sell
14,187
-2,607
-16% -$55.1K ﹤0.01% 1692
2023
Q2 		$362K Sell
16,794
-260,994
-94% -$7.05M ﹤0.01% 1637
2023
Q1 		$8.15M Buy
277,788
+11,769
+4% +$409K 0.01% 845
2022
Q4 		$9.83M Sell
266,019
-3,479
-1% -$123K 0.02% 790
2022
Q3 		$7.59M Sell
269,498
-145,800
-35% -$3.64M 0.01% 860
2022
Q2 		$8M Buy
415,298
+12,974
+3% +$154K 0.01% 839
2022
Q1 		$5.17M Buy
+402,324
New +$9.09M 0.01% 1132

Other funds holding AMLX

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Allspring Global Investments's AMLX Position: Q3 2024 in Review

Allspring Global Investments sold out of Amylyx Pharmaceuticals (AMLX) in Q3 2024, closing a stake of 28,785 shares — an estimated $54.7K sold.

Allspring Global Investments first reported a position in AMLX in Q1 2022 and held it in 10 quarters. The position peaked at $9.83M in Q4 2022. 110 funds tracked by Wall St. Rank hold AMLX as of Q3 2024.

  • Allspring Global Investments reported no remaining Amylyx Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Allspring Global Investments sold 28,785 Amylyx Pharmaceuticals shares in Q3 2024, an estimated $54.7K.
  • Allspring Global Investments first reported a position in Amylyx Pharmaceuticals in Q1 2022 and held it in 10 quarters.
  • Allspring Global Investments's Amylyx Pharmaceuticals position peaked at $9.83M in Q4 2022.
  • 110 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2024.

Based on Allspring Global Investments's 13F filing for Q3 2024, filed 18 Oct 2024.